Deanna Protocol Ameliorates the Deficits in Human iPSC ‐Cortical Neurons Carrying Familial Alzheimer's Mutation
CNS Neuroscience & Therapeutics · 2026-10 · 32 (10)
DOI: 10.1002/cns.71205 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 23.10.2026. Verfasst von Leticia Keler Soares und 6 weiteren Autor:innen. Beteiligte Einrichtung: University of Central Florida, Orlando, Florida, USA. Hauptthemen laut MEDLINE: Induced Pluripotent Stem Cells, Alzheimer Disease, Presenilin-1, Neurons. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, National Institutes of Health, National Institute on Aging, Winning the Fight Against Neurodegenerative Diseases (WFND).
Themen: Demenz
Abstract (Originalsprache)
Aims
Deanna Protocol (DP) is an anaplerotic, mechanism‐based therapy designed to address impaired cellular energy flux. The present study aims to investigate the effects of DP in treating Alzheimer's disease (AD) by using cortical neurons derived from AD patient iPSCs carrying a PSEN1 mutation, while cortical neurons differentiated from iPSCs of a healthy subject serve as control.
Methods
PSEN1 cortical neurons were treated with DP acutely (24 h) and chronically (1–3 weeks). The effect of DP was assessed by utilizing TMRE assay for mitochondrial function, immunofluorescent staining for AD neuron morphological pathology, whole cell patch clamp for neuron electrophysiological property, and microelectrode array (MEA) analysis of long‐term potentiation (LTP) for neurocircuit function.
Results
PSEN1 cortical neurons demonstrated impaired mitochondrial function, elevated pathological biomarkers, reduced neurite complexity, altered electrophysiology, and decreased LTP. DP treatment significantly ameliorated all these phenotypes.
Conclusion
This study, while confirming iPSC‐ PSEN1 cortical neurons as a valid AD model, demonstrated the efficacy of DP on ameliorating structural and functional pathologies in AD neurons. It highlights that targeting energy production could be an effective approach in treating neurodegeneration in AD and suggests its potential efficacy in other neurodegenerative diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Central Florida, Orlando, Florida, USA.
- Hesperos Inc., Orlando, Florida, USA.
- WFND, Tampa, Florida, USA.
ORCID-Profile: Leticia Keler Soares, Gaurav Srivastava, Brianna Waggoner, James J Hickman, Xiufang Guo
Förderung
- NIA NIH HHS
- National Institutes of Health, National Institute on Aging
- Winning the Fight Against Neurodegenerative Diseases (WFND)
- National Institutes of Health
Zitieren
APA
Keler Soares, L., Srivastava, G., Dwelle, C., Waggoner, B., Tedone, V., Hickman, J. J., & Guo, X. (2026). Deanna Protocol Ameliorates the Deficits in Human iPSC ‐Cortical Neurons Carrying Familial Alzheimer's Mutation. CNS Neuroscience & Therapeutics, 32(10). https://doi.org/10.1002/cns.71205
Vancouver
Keler Soares L, Srivastava G, Dwelle C, Waggoner B, Tedone V, Hickman JJ, et al. Deanna Protocol Ameliorates the Deficits in Human iPSC ‐Cortical Neurons Carrying Familial Alzheimer's Mutation. CNS Neuroscience & Therapeutics. 2026;32(10). doi:10.1002/cns.71205
BibTeX
@article{KelerSoares2026,
author = {Keler Soares, Leticia and Srivastava, Gaurav and Dwelle, Camden and Waggoner, Brianna and Tedone, Vince and Hickman, James J and Guo, Xiufang},
title = {Deanna Protocol Ameliorates the Deficits in Human iPSC ‐Cortical Neurons Carrying Familial Alzheimer's Mutation},
journal = {CNS Neuroscience & Therapeutics},
year = {2026},
volume = {32},
number = {10},
doi = {10.1002/cns.71205}
}
EUVIMED